Disease-modifying mRNA targets in kidney cells

Disease-modifying mRNA targets in kidney cells refer to a broad class of genetic sequences and their corresponding messenger RNA (mRNA) transcripts that are targeted for therapeutic intervention in renal diseases. This approach encompasses two primary strategies: the delivery of synthetic mRNA to induce the expression of deficient or therapeutic proteins, such as VEGF-A for tissue repair or CTNS for cystinosis, and the use of inhibitory RNAs like siRNA or ASOs to silence pathogenic transcripts, such as APOL1 or specific solute carrier (SLC) proteins (AstraZeneca, 2022; Judo Bio, 2025). Targeting these molecules specifically within kidney cell populations, such as podocytes or proximal tubule epithelial cells, is a major focus of current drug development to avoid systemic side effects and liver sequestration (Frontiers in Pharmacology, 2023). Specialized delivery platforms, including lipid nanoparticles and ligand-conjugated oligonucleotides (e.g., Megalin-targeting STRIKERs), are employed to harness endogenous receptor-mediated endocytosis for precise renal uptake (Judo Bio, 2024). By modulating the expression of these targets, researchers aim to halt or reverse disease progression in conditions like polycystic kidney disease, Alport syndrome, and diabetic nephropathy (NIH, 2025). These therapies represent a shift toward precision medicine in nephrology, addressing the underlying molecular drivers of kidney dysfunction that were previously considered undruggable.

Other names

Renal mRNA targetsKidney-specific mRNA transcriptsmRNA-based kidney therapeuticsSolute carrier (SLC) mRNA targetsApolipoprotein L1 (APOL1) mRNAVascular endothelial growth factor A (VEGF-A) mRNA

Therapeutic strategies targeting these molecules involve the delivery of synthetic mRNA to induce the expression of deficient or therapeutic proteins (protein replacement therapy) or the use of inhibitory oligonucleotides (siRNA, ASO, or miRNA antagonists) to degrade pathogenic mRNA transcripts and silence disease-driving genes (Judo Bio, 2025; AstraZeneca, 2022). Delivery is typically facilitated by lipid nanoparticles (LNPs) or ligand-conjugates that utilize receptor-mediated endocytosis, such as the Megalin (LRP2) receptor, to achieve cell-specific uptake in the proximal tubule or podocytes (Judo Bio, 2024; NIH, 2025).